especially given the improved standardization of measurements (7), thus, avoiding reliance on ultrastructural defects or even cilia beat pattern in select patients. While the test has some limitations (e.g., overlapping levels in individuals with cystic fibrosis), a recent multicenter study of 149 subjects with PCD and 224 healthy and disease controls showed that the technique was safe, easy to perform, highly reproducible, and had sensitivity and specificity of 0.98 and 0.99, respectively, in patients 5 years of age and older (7) . There is growing evidence that nasal nitric oxide levels may even discriminate PCD from other lung diseases in preschool populations (unpublished observations). Until genetic diagnosis is approved, we contend that a validated set of diagnostic criteria should include nasal nitric oxide levels.
